X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the clinical development of EG-70 (detalimogene voraplasmid) for the treatment of non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin treatment.
Lead Product(s): Detalimogene Voraplasmid
Therapeutic Area: Oncology Product Name: EG-70
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Adage Capital Partners
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 14, 2024
Details:
The financing will be used for the advancement of EG-70 (detalimogene voraplasmid) as an entirely new genetic medicine approach to treat BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Detalimogene Voraplasmid
Therapeutic Area: Oncology Product Name: EG-70
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 22, 2023
Details:
The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.
Lead Product(s): Detalimogene Voraplasmid
Therapeutic Area: Oncology Product Name: EG-70
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Forbion Growth
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 17, 2023
Details:
EG-70 is a novel non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. It is being investigated for NMIBC in patients with carcinoma in situ that are BCG-unresponsive.
Lead Product(s): EG-70
Therapeutic Area: Oncology Product Name: EG-70
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
The study design consists of an open label dose escalation Phase 1 study to evaluate the safety and tolerability of EG-70 and to determine the recommended Phase 2 dose, followed by a Phase 2 portion to evaluate efficacy and safety.
Lead Product(s): EG-70
Therapeutic Area: Oncology Product Name: EG-70
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
